Table 1.
Summary of overall data
| Factors | NHT Group (n=116) | Non-NHT Group (n=73) | p-value |
|---|---|---|---|
| Age (y) | 66.6 (SD±7.0) | 66.0 (SD±7.2) | 0.718* |
| Height (m) | 1.70 (IQR: 1.67–1.74) | 1.70 (IQR: 1.67–1.76) | 0.274# |
| Weight (kg) | 71.0 (SD±10.1) | 71.4 (SD±9.6) | 0.802* |
| BMI (kg/m2) | 24.50 (SD±2.90) | 24.32 (SD±2.77) | 0.783* |
| Volume of Prostate before NHT | 46.45 (IQR: 33.95–65.12) | / | / |
| Preoperative Volume | 31.50 (IQR: 22.25–46.15) | 32.09 (IQR: 24.50–42.95) | 0.629# |
| Diabetes | 19 (16.4%) | 11 (15.1%) | 0.810※ |
| History of Abdominal or Pelvic Surgery | 22 (19.0%) | 2 (2.7%) | 0.001※ |
| Choice of NHT | |||
| ARA alone | 32 (27.6%) | / | / |
| GnRH agonist alone | 3 (2.6%) | / | / |
| Combination | 81 (69.8%) | / | / |
| Treatment Time of NHT | |||
| ≤3 months | 87 (75.0%) | / | / |
| 3–6 months | 20 (17.2%) | / | / |
| >6 months | 9 (7.8%) | / | / |
| PSA before Biopsy | 19.96 (IQR: 11.86–33.25) | / | / |
| Preoperative PSA | 2.69 (IQR: 0.65–6.73) | 17.60 (IQR: 8.60–24.22) | 0.001# |
| Gleason Score | 7.09 (SD±1.95) | 7.63 (SD±1.34) | 0.994* |
| OT (min) | 109.0 (IQR: 71.3–144.8) | 109.0 (IQR: 71.5–181.5) | 0.616# |
| EBL (mL) | 35.0 (IQR: 20.0–100.0) | 70.0 (IQR: 20.0–150.0) | 0.005# |
| Clinical Staging | |||
| T1 | 11 (9.5%) | 2 (2.7%) | 0.075※ |
| T2 | 72 (62.1%) | 28 (38.4%) | 0.001※ |
| T3a | 9 (7.8%) | 32 (43.8%) | 0.001※ |
| T3b | 19 (16.4%) | 11 (15.1%) | 0.001※ |
| T4 | 5 (4.3%) | 0 | 0.001※ |
| Pathological Staging | |||
| T0 | 4 (3.4%) | 0 | 0.001※ |
| T2 | 55 (47.4%) | 17 (23.3%) | 0.001※ |
| T3a | 21 (18.1%) | 27 (37.0%) | 0.004※ |
| T3b | 34 (29.3%) | 29 (39.7%) | 0.139※ |
| T4 | 2 (1.7%) | 0 | 0.001※ |
| PSM rate | 31.0% (36/116) | 28.8% (21/73) | 0.741※ |
| LOS (d) | 4 (IQR: 4–6) | 5 (IQR: 4–6) | 0.094# |
| DD (d) | 3 (IQR: 3–4) | 4 (IQR: 3–4) | 0.122# |
Notes: *Analysis of variance, # the Kruskal–Wallis test, ※ Pearson’s chi-square test.
Abbreviations: BMI, body mass index; PSA, prostate specific antigen; NHT, neoadjuvant hormone therapy; ARA, androgen receptor antagonists; OT, operative time; EBL, estimated blood loss; PSM, positive surgical margins; LOS, hospital length of stay; DD, drainage duration.